



# R.A.I.S.E 1.0: Revolutionizing Advancements In SLE For Excellence

**22<sup>nd</sup> Mar 2025, 5:00pm - 8:00pm**  
**Hilton Kuala Lumpur**

Time	Agenda	Speakers
5:00pm – 5:30pm	Registration	
5:30pm – 5:35pm	Opening Remarks by Chairperson	Dr Chow Sook Khuan, (Consultant Rheumatologist, Sunway Medical Centre)
5:35pm – 6:05pm	<b>Lupus Nephritis: Renal Protection and Role of Belimumab</b>	<b>Prof Dr Med Hans-Joachim Anders,</b> (Professor of Internal Medicine / Nephrology, Germany)
6:05pm – 6:20pm	<b>My Experience with Benlysta: A Case Study</b>	
6:20pm – 6:35pm	Panel Discussion & Closing	Prof Dr Anders, Dr Chow Sook Khuan, Dr S. Prasad Menon, (Consultant Nephrologist, SJMC)
6:35pm – 7:15pm	Break	
7:15pm	Dinner	

**Scan Here To Register**

Meet us at Hilton KL

Join us virtually



RSVP please contact: **Wai Kuan 012 - 517 1047**  
Kindly advise if vegetarian meal is preferred.

This educational program  
is brought to you by:





**Chairperson:**

**Dr Chow Sook Khuan**, MBBS (Mal), M. Med (Mal), MRCP (Edin), FRCP (Lond), FACR (USA), RhMSUS (USA), FAMM, CIPS (USA)

Dr Chow Sook Khuan is a Consultant Rheumatologist at Sunway Medical Centre. She earned her MBBS and Master of Medicine (M.Med) degrees from University of Malaya. She further obtained the Membership of Royal College of Physicians (MRCP) from Edinburgh. Her commitment to continuous professional development is evident through her fellowships with esteemed institutions, including Royal College of Physicians (London), the American College of Rheumatology, and the Academy of Medicine Malaysia. Additionally, she holds certifications such as RhMSUS and CIPS from USA. In her clinical practice, Dr Chow focuses on the diagnosis and management of various autoimmune and rheumatic conditions. Her area of expertise encompasses autoimmune disease and biologicals treatment in autoimmune disease.



**Speaker:**

**Prof Dr Med Hans-Joachim Anders**, MD

Prof Dr Hans-Joachim Anders attended medical school at the Universities of Göttingen and Würzburg and performed his MD thesis in experimental cardiology. He received his clinical training at the University of Munich under the guidance of Detlef Schlöndorff and became a board-certified internist, nephrologist, rheumatologist, and immunologist. He directs the Division of Nephrology at the Inner City Campus of the University of Munich with its inpatient and outpatient services and personally runs a lupus nephritis clinic. As a professor of nephrology at the University of Munich, he teaches all aspects of clinical nephrology and coordinates the Medical Faculty's "Molecular Medicine" fellowship program for medical students. His own international research lab focuses on the molecular mechanisms of kidney injury, inflammation, and repair with a special interest in translational aspects and preclinical drug testing. He has published more than 350 original articles, reviews, and book chapters and received several national and international awards, e.g., the award for outstanding contributions in basic science in nephrology of the European Renal Association (2018). At present, Dr Anders is associate editor of JASN and NDT and serves the ERA and the ISN in various boards devoted to clinical nephrology as well as experimental and translational research.



**Panelist:**

**Dr S. Prasad Menon**, MBBS (Ind), MRCP (UK), FRCP (Edin), FIAMS (Ind) AM (Mal)

Dr S. Prasad Menon is a Consultant Nephrologist at Subang Jaya Medical Centre, with extensive experience in kidney diseases. He has held key leadership roles in nephrology societies and medical organizations, including serving as President of Malaysia Society of Nephrology. Dr Prasad earned his MBBS at Banaras Hindu University India, followed by postgraduate training in Malaysia, the UK, and Australia. He is board-certified by the Royal College of Physicians (UK) and holds an FRCP (Edin) and FIAMS. Dr Prasad is highly regarded for his contributions to nephrology, medical education, and research.

**Benlysta (belimumab) Safety Information:** BENLYSTA is contraindicated in patients who have demonstrated anaphylaxis to BENLYSTA.

**Warnings and Precautions:** Serious Infections: As with other immunomodulating agents, the mechanism of action of BENLYSTA may increase the risk for the development of infections. In controlled clinical studies, the incidence of serious infections was similar across the BENLYSTA and placebo groups; however, fatal infections (e.g. pneumonia and sepsis) occurred more frequently in patients receiving Benlysta compared with placebo. BENLYSTA should not be initiated in patients with active serious infections (including serious chronic infections).

**Reference:** 1. Benlysta Prescribing Information.

By registering for the event, the Healthcare Professionals (HCP) consents to the disclosure of the HCP's Personally Identifiable Information (PII) such as the registration particulars and webcast log-in details to GlaxoSmithKline Pharmaceutical Sdn Bhd. Please refer our Privacy Notice at: <https://privacy.gsk.com/en-my/hcp/>



**For Malaysia Healthcare Professionals Only**

GlaxoSmithKline Pharmaceutical Sdn Bhd 195801000141 (3277-U)  
 HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama,  
 Bandar Utama, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia.  
 Tel: (603) 2037 9808 [www.my.gsk.com](http://www.my.gsk.com)

Trade marks are owned by or licensed to the GSK group of companies.  
 Adverse events should be reported to [drugsafetyinfo.my@gsk.com](mailto:drugsafetyinfo.my@gsk.com)  
 © 2025 GSK group of companies or its licensor.

Before prescribing, please refer to the full prescribing information by scanning this QR code. For any issues accessing the prescribing information via QR code, please contact GSK Malaysia at [medinfo.my@gsk.com](mailto:medinfo.my@gsk.com).